Tiziana Life Sciences Ltd.
London
United Kingdom
211 articles about Tiziana Life Sciences Ltd.
-
Tiziana Life Sciences plc ("Tiziana" or the "Company") - Tiziana Files Registration Statement on Form F-3 with U.S. Securities and Exchange Commission
1/27/2021
Tiziana Life Sciences plc, a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces that it has filed a “universal” shelf registration statement on Form F-3 with the U.S. Securities and Exchange Commission in relation to up to US$250,000,000 in market value of its securities.
-
Tiziana Life Sciences to Participate in a Fireside Chat at B. Riley Virtual Oncology Investor Conference on 21 January 2021 at 3 pm ET/8 pm GMT
1/20/2021
Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced its CEO and CSO, Dr. Kunwar Shailubhai, will participate in a fireside chat via a video link on Thursday 21 January 2021 at 3 pm ET /
-
Tiziana Life Sciences plc ("Tiziana" or the "Company") - AIM Delisting and Admission to the Standard Listing Segment of Main Market
1/20/2021
Tiziana Life Sciences plc provided a further update with respect to the cancellation of admission of its Ordinary Shares to trading on AIM and admission to listing of its ordinary shares on the standard listing segment of the Official List of the Financial Conduct Authority and admission to trading on the main market for listed securities of London Stock Exchange plc .
-
Tiziana announces appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer
1/13/2021
Tiziana Life Sciences plc, a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces the appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer.
-
Tiziana Life Sciences to Present at Biotech Showcase Digital 2021
1/11/2021
Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announced that it is participating in Biotech Showcase™ 2021 and providing an on-demand company presentation. Registered attendees to Biotech Showcase can now access recorded company presentations prior to the actual event. 24x7 on-demand acc
-
Tiziana Life Sciences to participate at J.P. Morgan Healthcare Conference 2021
1/11/2021
Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announced that it is participating in the J.P. Morgan 39th Annual Healthcare Conference 2021. Dr. Kunwar Shailubhai, CEO and CSO of Tiziana Life Sciences, commented, “I look forward to sharing our exciting story with conference attendees. W
-
Tiziana Life Sciences plc announces completion of the clinical trial with nasally administered Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, for the treatment of COVID-19 patients in Brazil
1/4/2021
The scientific approaches underlying this clinical study could potentially be effective against SARs, MERS, and all variants of coronaviruses
-
Tiziana Life Sciences PLC (“Tiziana” or “the Company”) - Notification of proposed admission to the Main Market and cancellation of trading on AIM
12/17/2020
Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (" Tiziana " or the " Company "), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces it has applied to list its ordinary shares ("Ordinary Shares") on the standard listing segment of the Official List of the Financial Conduct Authority (“FCA”) (the "Official List") and admission to trading on the London Stock Exc
-
Tiziana Life Sciences to Host Investor Update Call on 2 December 2020 at 4:15 p.m. ET
12/1/2020
Tiziana Life Sciences plc, a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announced its CEO and CSO Dr. Kunwar Shailubhai will host a conference call on Wednesday, 2 December 2020 at 4:15 p.m. ET to provide updates on the Company.
-
Tiziana Life Sciences PLC ("Tiziana" or the "Company") - PDMR Dealing
11/18/2020
Tiziana Life Sciences plc, a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 45,000 ordinary shares of 3p each in the market at a price of 84p per share.
-
Tiziana Life Sciences announces collaboration with Parexel Biotech to conduct phase 1b/2 clinical trial in patients with Crohn’s Disease
11/11/2020
Potential to be a safer and effective alternative to the intravenous immunotherapies currently used for Crohn’s Disease
-
Tiziana Announces Initiation of Clinical Trial with Covid-19 Patients in Brazil with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody
11/2/2020
Tiziana Life Sciences plc, a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces initiation of a collaborative clinical study investigating nasally administered Foralumab either alone or in combination with orally administered dexamethasone in COVID-19 patients in Brazil.
-
Tiziana Life Sciences Announces Timetable of Demerger of Accustem (for holders of Tiziana ADRs)
10/27/2020
Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (" Tiziana " or the " Company "), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it is confirming the timetable for the Accustem Sciences Limited (" Accustem ") demerger (the " Demerger ") for holders of the Company’s American Depositary Receipts (“ADRs”). The demerger of Accustem is the spinoff of Tiz
-
Tiziana Life Sciences Plc (the "Company") - Result of General Meeting
10/2/2020
At the General Meeting of the Company held at 11.00 a.m. on 2 October 2020, both of the resolutions were duly passed.
-
Tiziana Life Sciences plc: Publication of Research Note
9/21/2020
Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (" Tiziana " or the " Company "), is pleased to note the publication of a new analyst research note from H C Wainwright & Co which is available on the Company’s website at https://ir.tizianalifesciences.com/static-files/0bae55ef-6589-43f2-a4bd-65be16b3dce1 About Tiziana Life Sciences Tiziana Life Sciences plc is a dual listed (NASDAQ: TLSA & UK AIMS: TILS) biotechnology c
-
Tiziana Life Sciences plc to Conduct a Clinical Study with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients in Brazil
9/17/2020
Nasal Administration of Foralumab is a potentially transformative approach for treating patients with Covid-19
-
Tiziana Life Sciences Plc ("Tiziana" or the "Company") - Demerger of StemPrintER and Distribution in SpecieProposed capital reduction and notice of General Meeting
9/16/2020
Tiziana Life Sciences Plc announces that, following a strategic review of its clinical trial programs and core focus, it intends to demerge its StemPrintER and SPARE genomics-based personalised medicine business into a separate and independent listed company, Accustem Sciences Limited.
-
Tiziana Life Sciences Announces Planned Spin Out of StemPrintER into a New Publicly Listed Company, Accustem SciencesTiziana Shareholders to receive 1:1 share dividend in Accustem Sciences
9/16/2020
Tiziana Life Sciences plc, a clinical stage biotechnology company developing targeted drugs for cancer, inflammatory diseases and COVID-19, and focused on innovative therapeutics for oncology, inflammation and infectious disease, announced plans for demerging its StemPrintER asset into a separate and independently listed public company, Accustem Sciences Limited.
-
Tiziana Life Sciences Clarifies Reason for Filing an Amended ADS Registration Statement
8/28/2020
Tiziana Life Sciences plc, a clinical stage biotechnology company developing targeted drugs for cancer, inflammatory diseases and COVID-19, announced the clarification of the reason for filing a corrected amendment registration statement on Form F-6 registering additional American Depositary Shares.
-
Tiziana Life Sciences CEO Updates Shareholders on its Patent Portfolio, Clinical Pipeline, and Strategy in an Exclusive Interview
8/27/2020
Tiziana Life Sciences plc, a clinical stage biotechnology company developing targeted drugs for cancer, inflammatory diseases and COVID-19, announced that an interview with its CEO and CSO Dr. Kunwar Shailubhai is now available.